Novo Nordisk shares jump up on latest weight-loss drug trial results - Financial Times
- Novo Nordisk shares jump up on latest weight-loss drug trial results Financial Times
- Novo Nordisk Shares Surge on New Obesity Drug Results The Wall Street Journal
- Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity Yahoo Finance
- Why Novo Jumped — And Took Out Lilly And Viking Stocks Investor's Business Daily